Dr. Waqqas Afif
If you are interested in learning more about any of the clinical and research studies below or would like to volunteer as a research subject, please email: miirecherche.ibdresearch@muhc.mcgill.ca.
Study Title: The Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial)
Collaboration with Dr. Laura Targownik and Dr. Mark Silverberg, Toronto Immune & Digestive Health Institute (TIDHI) Innovation Inc.
Study Title: SHIFT-IBD: Switching to high-efficacy anti-IL-23 guselkumab in ustekinumab exposed persons with active IBD
Study Title: Pilot study to assess de-escalation of ustekinumab therapy in patients with Crohn’s disease
Dr. Matthieu Allez
Dr. Talat Bessisow
If you are interested in learning more about any of the clinical and research studies below or would like to volunteer as a research subject, please email: miirecherche.ibdresearch@muhc.mcgill.ca.
Collaboration with Dr. Jeffrey McCurdy, Ottawa Hospital Research Institute
Study Title: Evaluating fistula outcomes after seton removal in patients with perianal Crohn’s disease: UNFASTEN-PCD
Collaboration with Dr. Christopher Ma, MD MPH, University of Calgary
Study Title: Real-World Effectiveness and Safety of Upadacitinib for Achieving Endoscopic Remission in Moderate-to-Severely Active Ulcerative Colitis Phase IV : REMIT-UC
Collaboration with Dr. Bruce Mazer, McGill University Health Center
Study Title: Transdisciplinary Centre for Biological Therapies Biobank and Registry
Collaboration with Mayo Clinic Arizona
Study Title: Treat-to-Target of Endoscopic Remission in Patients with IBD in Symptomatic Remission: The QUOTIENT Trial
Collaboration with Dr. Neeraj Narula, Hamilton Health Sciences
Study Title: Comparison of medical RESCUE strategies for patients with steroid-refractory acute severe Ulcerative Colitis: an open-label randomized controlled trial: RESCUE-UC
Dr. Alain Bitton
If you are interested in learning more about any of the clinical and research studies below or would like to volunteer as a research subject, please email: rita.kohen@muhc.mcgill.ca.
The following 4 studies are part of NIH-NIDDK IBD Genetics Consortium (IBDGC)
- Identifying genes responsible for inflammatory bowel disease
- Mechanisms of microbiota in mucosal inflammation across the biologic demarcation of Ulcerative Colitis
- Mechanisms of intestinal inflammation following ileal resection for Crohn’s Disease
- Understanding the Genetics of Inflammatory Bowel Disease: The Diversity Study
Sponsor: Dr. John D. Rioux, Montreal Heart Institute
Funding: Génome Canada (Rioux), National Institutes of Health (Rioux) and Pfizer Canada Inc. (Rioux)
Study Title: iGenoMed – CHUM: Identification of biomarkers of response to molecularly-targeted therapies in inflammatory bowel diseases
Study Title: Inflammatory Bowel Disease Epidemiology, Future Burden and Cancer Risk in Québec and Canada
as part of an initiative by the Canadian Gastro-Intestinal Epidemiology Consortium – pending approval
Collaboration with Dr. Jose Teodoro, McGill University
Study Title: Modulation of fatty acid esters of hydroxy fatty acids (FAHFA) levels in the intestine via G0S2 inhibition
Dr. Alain Bitton & Dr. Terry Sigman
Sponsor: Dr. Kenneth Croitoru, Mount Sinai Hospital, Toronto ON with funding from Crohn’s and Colitis Canada
Study Title: A Multidisciplinary Human Study on the Genetic, Environmental and Microbial Interactions that Cause IBD (GEM Project)
Dr. Peter Lakatos
If you are interested in learning more about any of the clinical and research studies below or would like to volunteer as a research subject, please email: rita.kohen@muhc.mcgill.ca
Study Title: Quality of Care Assessment of the MUHC IBD Center: Retrospective and Prospective Assessment of Quality or Care and Outcome Parameters before and after Installation of the IBD Center – on hold
Study Title: Clinical Outcomes and Therapeutic Drug Monitoring Following Switching from Intravenous Vedolizumab to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease; An Observational Study
Study Title: Clinical Outcomes and Therapeutic Drug Monitoring Following New Start or Switching from Infliximab Originator to Subcutaneous Biosimilars in Patients with Inflammatory Bowel Disease: an Observational Study
Study Title: Clinical Outcomes Following Switching from Ustekinumab Originator to Biosimilars in Patients with Inflammatory Bowel Disease: an Observational Study
Collaboration with Dr. Derek Rosenzweig, McGill University
Study Title: Biofabrication of a 3D gut-on-a-chip model of human inflammatory bowel disease